Mikhail Karim CBER
Biotech

CBER Director Mikhail feels FDA is ‘getting back to stability’

In an interview with Fierce, Karim Mikhail explained why the organization is now “on the right track,” with former colleagues returning to the FDA.
Marissa Russo Oct 21, 2026 8:00am
Saudi Arabia takes actionable steps to build its biotech sector after 46 agreements in Riyadh

Saudi Arabia takes actionable steps to build its biotech sector

In Laboratory Over the Shoulder View of Scientist in Protective Clothes Doing Research on a Personal Computer

Using tumor ‘avatar’ to predict patients’ immunotherapy response

Oct 21, 2026 11:50am
From Scientific Hypothesis to Clinical Practice The Next Chapter for CLDN182

The next chapter of CLDN18.2-directed innovation

Brought to you by Astellas Pharma US
GSK

Amid bepirovirsen triumph, GSK scraps trial of next-gen therapy

Oct 21, 2026 9:35am
Aligning drug discovery around patient benefit from the outset Connecting human insights to better decisions

Aligning drug discovery around patient benefit from the outset: Connecting human insights to better decisions

Brought to you by IQVIA Laboratories
More News

Roche builds blockbuster case in MS as FDA decision approaches

Oct 21, 2026 9:30am

Astellas links up with AI Proteins in $400M drug discovery deal

Oct 21, 2026 9:14am

Reverse mergers rebound to highest level since 2021: report

Oct 21, 2026 3:12am

Advocacy org uses dashboard to identify trial sites' performance

Oct 21, 2026 2:00am